CTLA-4 inhibitors are more commonly linked to colitis, hypophysitis, and rash, whereas PD-1/PD-L1 inhibitors are more often associated with thyroid dysfunction and pneumonitis. The gene discussed is CTLA4; the disease is hypophysitis.